Amira has reported initial positive data from Phase 1 clinical study of AM211, the company’s oral selective antagonist of the DP2 (also known as CRTH2) receptor. It is intended for the treatment of respiratory diseases like, asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis.
The interim results demonstrate that a sustained pharmacodynamic effect can be achieved with a single dose of AM211.
The pharmacokinetic profile indicates safety multiples as compared to exposures observed in safety species.
Isabelle DeArmond, Vice President of Clinical Development at Amira, said: “The AM211 clinical PD data confirms what we previously observed in pre-clinical models. While a great deal of clinical work remains on this program, we are particularly excited since we believe DP2 antagonism would be a novel therapeutic approach to various respiratory diseases.”